Navigation Links
Watson Confirms Renvela® for Oral Suspension Patent Challenge
Date:7/12/2010

MORRISTOWN, N.J., July 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet.  Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela® for Oral Suspension.  Renvela ® is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease who are on dialysis.

Genzyme Corporation filed suit against Watson on July 9, 2010 in the United States District Court for the District of Maryland seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,667,775.  Genzyme's suit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  Based on available information, Watson believes it may be a first applicant to file an ANDA requesting approval of a generic version of Renvela®  for oral suspension, and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity for this dosage form.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and dist
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
2. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
3. Watsons Generic Prograf® 5 mg Receives FDA Approval
4. Watson Launches Generic Exelon®
5. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
6. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
7. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
8. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
9. Watson Launches Generic Version of LIPITOR® in Canada
10. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
11. Watson Reaches Settlement with Teva Over Seasonale(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013 Amgen (NASDAQ: AMGN ... Annual  Healthcare Conference on Thursday, May 30, 2013, at the ... at 9:20 a.m. Eastern Daylight Time. Arvind Sood ... present at the conference. Live audio of the presentation can ... www.amgen.com , under Investors. A replay of the webcast will ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ... CSKI ), a leading fully integrated pharmaceutical company ... ("PRC"), today announced that it held its 2011 Annual ... 2011, in Harbin, PRC. At the Annual ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") ... in-vitro diagnostic ("IVD") company, today announced that China,s State ... Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene ... companion diagnostic test for the use of a targeted ...
Cached Medicine Technology:China Sky One Medical, Inc. Elects Board Directors at its Annual Shareholders Meeting 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
(Date:5/23/2013)... 2013 Voyance, the ASC industry’s ... tools, and ASCA, the industry’s national membership association, ... Benchmarking Program. Voyance will leverage their ... benchmarking experience to support ASCA’s goal to provide ... tool. , “Voyance is both excited and proud ...
(Date:5/23/2013)... 23, 2013 Onlinefitnessreview.com recently published a ... to determine what makes this diet work and how ... highlights three main components of the program: eliminating foods ... mindset and the personal motivation that is needed to ... days to keep the metabolism rate in top gear. ...
(Date:5/23/2013)... (HealthDay News) -- People who eat at fast-food restaurants ... and teens are the worst offenders, a new study ... their meals by as much as 34 percent, parents ... and adults by as much as 20 percent," study ... release from the Robert Wood Johnson Foundation, which helped ...
(Date:5/23/2013)... Susquehanna Health is now a ... training course for adolescents age 11 and up. ... Dr. Patricia Keener after a colleague’s toddler choked to ... who didn’t know how to provide first aid. Safe ... medical basis that aims to reduce the number of ...
(Date:5/23/2013)... "triple negative" carries a poor prognosis, with limited treatment ... cancer cells the way it,s supposed to. New research ... respond to chemotherapy, and identifies a mechanism to rectify ... Li, PhD, and his team at Western,s Schulich School ... Numb functions to promote the death of cancer cells ...
Breaking Medicine News(10 mins):Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3
... risk, as did smoking, study found , , WEDNESDAY, May ... beer, may hasten the onset of pancreatic cancer, according ... Digestive Disease Week 2008 conference in San Diego. , ... liquor or wine in lowering the age of onset ...
... so sensitive that it can tell whether or not ... towards cancer development may revolutionize how future colonoscopies are ... Fla. , Investigators have found that technology known ... determine whether a colon polyp is benign (not precancerous) ...
... to Reduce Bureaucracy, Streamline Decision Making, INDIANAPOLIS, May ... today announced changes across its executive leadership,structure as the ... in,a challenging business environment., "Earlier this year I ... their respective areas to determine if they were optimally ...
... 21 As fast-food marketers launch,programs across the ... a time-pressured society -- one that is already ... is responding by extending an,innovative local health program ... the nation., Two years ago, the company ...
... May 21 The following is a,statement by Steve Case, ... of Senator Ted Kennedy,s brain cancer diagnosis:, "I was ... tumor.,Just two weeks ago I had the opportunity to testify ... redouble our nation,s efforts to fight,cancer, and was able to ...
... new study, patients are receiving estimated doses of radiation from ... that may be detrimental to their long term health, putting ... emergency physicians have not been made aware of the cumulative ... currently have no way to know or estimate any given ...
Cached Medicine News:Health News:Beer Drinking May Speed Pancreatic Cancer Onset 2Health News:Beer Drinking May Speed Pancreatic Cancer Onset 3Health News:Beer Drinking May Speed Pancreatic Cancer Onset 4Health News:Virtual biopsy can tell whether colon polyp is benign without removal, Mayo researchers say 2Health News:Lilly Announces Changes in Key Leadership Roles 2Health News:Lilly Announces Changes in Key Leadership Roles 3Health News:Lilly Announces Changes in Key Leadership Roles 4Health News:Lilly Announces Changes in Key Leadership Roles 5Health News:Capital BlueCross Goes National for Health 2Health News:Cumulative radiation exposure shows increased cancer risk for emergency department patients 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Prevent dental and soft tissue damage. Used ... X-ray. Light-guided intubation is based upon the ... neck. This technique takes advantage of the ... the esophagus. A well-defined, circumscribed glow can ...
Medicine Products: